ArticleDiscover oncology2025
Inflammation related proteins and PLCG1 may contribute to papillary thyroid carcinoma risk through a potential regulatory axis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human lncRNA, hLinfRNA7 (IDO1-AS) Regulates Cytokine Expression, Tryptophan Catabolism, and Inflammatory Response in Macrophage.Molecular and cellular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPapillary thyroid carcinoma (PTC) is usually indolent, but a subset of patients shows aggressive behavior. Understanding protein-level mechanisms is essential for identifying new therapeutic targets. MATERIALS AND
methodsWe integrated protein quantitative trait loci (pQTL)-based Mendelian randomization (MR), transcriptomic validation, and mediation analysis to investigate protein-level causal pathways in PTC. Genome-wide association study (GWAS) summary statistics for PTC were obtained from the FinnGen cohort (2400 cases, 78,749 controls). Candidate proteins were selected based on prior evidence of involvement in pyroptosis-related pathways, including phospholipase C gamma 1 (PLCG1), which has been functionally linked to inflammation-associated cell death. pQTL data were sourced from the UK Biobank (UKB) and deCODE datasets. Two-sample MR was conducted using the inverse variance weighting (IVW) method, with sensitivity analyses for pleiotropy and heterogeneity. Mediation analysis was used to estimate indirect effects of upstream proteins on PTC risk via PLCG1. Differential expression was assessed using data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) project via the Gene Expression Profiling Interactive Analysis 2 (GEPIA2) platform.
resultsAmong 11 pyroptosis-related proteins with available pQTL instruments, the genetically predicted plasma level of phospholipase C gamma 1 (PLCG1) was significantly associated with reduced PTC risk (OR = 0.679, 95% CI 0.520–0.887, p = 0.004). Its downregulation in tumor tissues was confirmed by RNA-sequencing data from TCGA-THCA (p < 0.001). We next performed MR using data from the UKB-PPP, identifying 118 proteins with FDR-significant causal associations with PTC risk (FDR < 0.1), including 58 protective and 60 risk-enhancing proteins. Of the 118 proteins, 28 were causally associated with PLCG1 expression, with inflammation-related proteins comprising the largest proportion (46.4%). Mediation analysis revealed that SMPD3 (25.21%, p = 0.008), SIRT1 (22.70%, p = 0.007), and PPM1B (19.91%, p = 0.005) exerted significant indirect effects on PTC risk via PLCG1. These proteins were also downregulated in tumor tissues, with SMPD3 showing the most pronounced decrease (log₂FC = − 1.303, adjp = 3.63 × 10−127).
conclusionOur study findings suggest a potential regulatory axis in which inflammation-related proteins, such as SMPD3, may influence the risk of papillary thyroid carcinoma (PTC) through the pyroptosis-associated mediator PLCG1. These associations suggest a possible protein-level pathway in PTC, with SMPD3 and PLCG1 as promising molecular candidates, although further experimental validation is required to confirm their functional roles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.